Lv1
70 积分 2024-01-17 加入
Association of metabolic dysfunction-associated fatty liver disease with kidney disease
26天前
已完结
MASH and liver fibrosis: Clinical trials to watch
27天前
已完结
Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities
29天前
已完结
Idiopathic pulmonary fibrosis: aligning murine models to clinical trials in humans
1个月前
已完结
Idiopathic pulmonary fibrosis: aligning murine models to clinical trials in humans
1个月前
已完结
NASH drug treatment development: challenges and lessons
1个月前
已完结
Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial
1个月前
已完结
Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment
1个月前
已完结
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
1个月前
已完结
Metabolic Dysfunction–Associated Steatotic Liver Disease
1个月前
已完结
皖公网安备34019202002308
